Filing excerpt
For the three months ended September 26, 2026, we also recorded $13 million of inventory write-downs related to the market exit of the Medline Brand beds after initial communication to the FDA of plans to exit in September. We currently estimate the incremental related costs, including inventory write-downs, to be approximately $60 million to $210 million, which are expected to be incurred in the fourth quarter of 2026 and 2027 and to be excluded from Adjusted EBITDA.